Quest PharmaTech Inc. (Quest) is a biotechnology company. The Company is engaged in the discovery, development and commercialization of pharmaceutical products. It is developing a portfolio of product candidates for the treatment of cancer by combining immunotherapeutic antibodies with chemotherapy, photodynamic therapy, radio immunotherapy or immunoadjuvants. Quest is also developing a series of products for the treatment of cancer and dermatological conditions, based on the Company�s SonoLight Technology platform. Quest is developing high affinity monoclonal antibodies targeting certain tumour associated antigens that are presented in various cancers, including ovary, pancreas, lung, breast, prostate and stomach. Quest is developing the affinity monoclonal antibody Oregovomab (MAb B43.13) for the treatment of ovarian cancer.